Navigation Links
Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Date:10/23/2008

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's third quarter results and provide a corporate update, including an update on the ongoing development activities for picoplatin, the Company's lead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Caroline Loewy, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the call beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) on Thursday, October 30. A press release for the third quarter ended September 30, 2008, will be released after markets close on October 30.

To participate in the live call by telephone, please dial 877-419-6593 from the U.S. or 1-719-325-4885 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):New understanding of how to prevent destruction of a tumor suppressor 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3The Dr Oz Show and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houstons Reliant Convention Center on September 57925 1The Dr Oz Show and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houstons Reliant Convention Center on September 57925 2The Dr Oz Show and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houstons Reliant Convention Center on September 57925 3The Dr Oz Show and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houstons Reliant Convention Center on September 57925 4The Dr Oz Show and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houstons Reliant Convention Center on September 57925 5Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 1Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 2Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 3Prostate cancer patients on hormone therapy at increased risk for various heart diseases 57921 4Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine 57916 1Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine 57916 2